Rhythm BiosciencesFRA:0RY -7.96%31 EV-to-FCF is -5.40 as of Jul. 01, 2026. GuruFocus rates FRA:0RY with a GF Score™ of 31/100. The stock has 5 warning signs investors should review. Among 97 Medical Diagnostics & Research companies, Rhythm Biosciences ranks worse than 1030926.8% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Rhythm Biosciences's Enterprise Value is €18.60 Mil.
Rhythm Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.45 Mil. Therefore, Rhythm Biosciences's EV-to-FCF for today is -5.40.
The historical rank and industry rank for Rhythm Biosciences's EV-to-FCF or its related term are showing as below:
FRA:0RY'
s EV-to-FCF Range Over the Past 10 Years
Min: -5.56 Med: 0 Max: 0
Current: -5.56
FRA:0RY's EV-to-FCF is ranked worse than 100% of 97
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.51
vs FRA:0RY: -5.56
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Rhythm Biosciences's PE Ratio (TTM) for today is calculated as:
Rhythm Biosciences's share price for today is €0.052.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rhythm Biosciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.013.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Rhythm Biosciences EV-to-FCF Related Terms
Rhythm Biosciences EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Rhythm Biosciences's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Rhythm Biosciences's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Rhythm Biosciences EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Rhythm Biosciences's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Rhythm Biosciences's EV-to-FCF falls into.
Rhythm Biosciences's current Enterprise Value is €18.60 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Rhythm Biosciences's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €-3.45 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Rhythm Biosciences (FRA:0RY) has a EV-to-FCF of -5.40 as of Jul. 01, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rhythm Biosciences and its competitors. According to the industry distribution chart, Rhythm Biosciences ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry.
Is Rhythm Biosciences' EV-to-FCF too high?
Rhythm Biosciences' current EV-to-FCF is -5.40. Based on the distribution chart, Rhythm Biosciences ranks #999999 out of 97 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Rhythm Biosciences has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Rhythm Biosciences' EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Rhythm Biosciences ranks #999999 out of 97 companies for EV-to-FCF. This places Rhythm Biosciences in the lower half of its industry. The industry median EV-to-FCF is 22.51. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.51, based on 97 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Rhythm Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Rhythm Biosciences's current EV-to-FCF is -5.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rhythm Biosciences stock overvalued right now?
Rhythm Biosciences (FRA:0RY) has a current EV-to-FCF of -5.40. The current EV-to-FCF is -5.40. Rhythm Biosciences' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Rhythm Biosciences (FRA:0RY), the current EV-to-FCF is -5.40 as of Jul. 01, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Rhythm Biosciences Ltd is a medical diagnostics technology company. It is engaged in developing and commercializing Australian medical diagnostics technology for sale to national and international markets. The product includes ColoSTAT a proposed diagnostic blood test for screening for colorectal cancer. The company operates predominantly in one business and geographical segment which is the research and development of biosciences in Australia.
31GF Score
Get the complete analysis for FRA:0RY
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:0RY has been successfully added to your 
